Related Experiment Videos
Dendritic cells internalize vaccine adjuvant after intramuscular injection
M Dupuis1, T J Murphy, D Higgins
1Cardiovascular Research Institute, University of California, San Francisco 94143, USA.
Cellular Immunology
|June 25, 1998
Summary
This study tracked the vaccine adjuvant MF59, revealing it interacts with antigen-presenting cells and travels to lymph nodes. MF59 enhances antigen presentation, significantly boosting antibody titers for improved vaccine efficacy.
Area of Science:
- Immunology
- Vaccinology
Background:
- Vaccine adjuvants are crucial for potent immune responses but their mechanisms remain unclear.
- Understanding adjuvant processing is key for rational vaccine design.
Purpose of the Study:
- To investigate the in vivo fate and cellular interactions of the MF59 adjuvant.
- To elucidate how MF59 influences antigen presentation and immune responses.
Main Methods:
- MF59 was labeled with a fluorescent dye (Dil) and co-injected with fluorescein-labeled gD2 antigen into mice.
- Tissue distribution and cellular localization of MF59 and antigen were analyzed at various time points using microscopy and immunofluorescence.
- Antibody titers against gD2 were measured serologically.
Main Results:
- MF59 was found in extracellular droplets and within cells in lymph nodes within hours of injection.
- At 48 hours, MF59 localized to dendritic cells and MHC class II+ cells at the injection site and in lymph nodes.
- MF59 co-localized with gD2 antigen, increased intracellular antigen levels, and led to a 207-fold rise in antibody titers.
Conclusions:
- MF59 is processed by antigen-presenting cells at the injection site and migrates to draining lymph nodes.
- MF59 enhances antigen presentation to T cells, leading to significantly improved antibody responses.